Post-hoc analysis shows improved patient-reported outcomes and biomarkers in ulcerative colitis patients, suggesting benefits of tulisokibart therapy.
Introduction: In the phase 2 ARTEMIS-UC trial, [1] 12 weeks of induction treatment with tulisokibart led to significant rates of clinical remission, endoscopic improvement and mucosal healing, and improvement in patient-reported outcome (PRO) measures and disease surrogate biomarkers in patients with moderately to severely active ulcerative colitis (UC).
No takes yet. Share an insight, caveat, or question.
Soßdorf et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: